Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone484-380-9263
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees17
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions
What is Madrigal Pharmaceuticals' stock symbol?
Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."
How were Madrigal Pharmaceuticals' earnings last quarter?
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) issued its earnings results on Wednesday, February, 27th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.74) by $0.01. During the same period in the prior year, the company posted ($0.67) EPS. View Madrigal Pharmaceuticals' Earnings History.
When is Madrigal Pharmaceuticals' next earnings date?
What price target have analysts set for MDGL?
14 equities research analysts have issued 12 month price targets for Madrigal Pharmaceuticals' shares. Their predictions range from $119.00 to $400.00. On average, they expect Madrigal Pharmaceuticals' stock price to reach $230.00 in the next year. This suggests a possible upside of 64.2% from the stock's current price. View Analyst Price Targets for Madrigal Pharmaceuticals.
What is the consensus analysts' recommendation for Madrigal Pharmaceuticals?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Madrigal Pharmaceuticals.
Has Madrigal Pharmaceuticals been receiving favorable news coverage?
Media stories about MDGL stock have trended somewhat negative on Thursday, according to InfoTrie. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Madrigal Pharmaceuticals earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days.
Who are some of Madrigal Pharmaceuticals' key competitors?
Some companies that are related to Madrigal Pharmaceuticals include Bausch Health Companies (BHC), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Loxo Oncology (LOXO), Perrigo (PRGO), Marina Biotech (MRNA), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), Catalent (CTLT), Nektar Therapeutics (NKTR), Alkermes (ALKS), Ascendis Pharma A/S (ASND), United Therapeutics (UTHR) and Array Biopharma (ARRY).
What other stocks do shareholders of Madrigal Pharmaceuticals own?
Who are Madrigal Pharmaceuticals' key executives?
Madrigal Pharmaceuticals' management team includes the folowing people:
- Dr. Paul A. Friedman, Chairman & CEO (Age 76)
- Dr. Rebecca A. Taub, Founder, Exec. VP of R&D, Chief Medical Officer and Director (Age 67)
- Mr. Marc R. Schneebaum, Sr. VP & CFO (Age 65)
- Mr. Thomas W. Hare, Sr. VP of Clinical Management
Who are Madrigal Pharmaceuticals' major shareholders?
Madrigal Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.46%), Jennison Associates LLC (1.83%), venBio Select Advisor LLC (1.46%), Northern Trust Corp (0.62%), Geode Capital Management LLC (0.59%) and Geode Capital Management LLC (0.59%). Company insiders that own Madrigal Pharmaceuticals stock include Bay City Capital Llc, Fred B Craves, Marc R Schneebaum, Paul A Friedman, Rebecca Taub and Richard S Levy. View Institutional Ownership Trends for Madrigal Pharmaceuticals.
Which major investors are selling Madrigal Pharmaceuticals stock?
MDGL stock was sold by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Victory Capital Management Inc., BlackRock Inc., FMR LLC, Great Point Partners LLC, Northern Trust Corp, Principal Financial Group Inc. and TD Asset Management Inc.. Company insiders that have sold Madrigal Pharmaceuticals company stock in the last year include Bay City Capital Llc, Marc R Schneebaum and Rebecca Taub. View Insider Buying and Selling for Madrigal Pharmaceuticals.
Which major investors are buying Madrigal Pharmaceuticals stock?
MDGL stock was acquired by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Norges Bank, Polar Capital LLP, Jennison Associates LLC, Citigroup Inc., Columbus Circle Investors, Artal Group S.A. and Candriam Luxembourg S.C.A.. Company insiders that have bought Madrigal Pharmaceuticals stock in the last two years include Fred B Craves, Paul A Friedman and Richard S Levy. View Insider Buying and Selling for Madrigal Pharmaceuticals.
How do I buy shares of Madrigal Pharmaceuticals?
Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Madrigal Pharmaceuticals' stock price today?
One share of MDGL stock can currently be purchased for approximately $140.09.
How big of a company is Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals has a market capitalization of $2.16 billion. The biopharmaceutical company earns $-32,810,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis. Madrigal Pharmaceuticals employs 17 workers across the globe.
What is Madrigal Pharmaceuticals' official website?
How can I contact Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at 484-380-9263 or via email at [email protected]
MarketBeat Community Rating for Madrigal Pharmaceuticals (NASDAQ MDGL)
MarketBeat's community ratings are surveys of what our community members think about Madrigal Pharmaceuticals and other stocks. Vote "Outperform" if you believe MDGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
